OncoDaily

Roupen Odabashian, Oncologist at Abbotsford Regional Hospital and Cancer Centre, Founder at MeDucation AI, Podcast Host at OncoDaily, shared on LinkedIn: “The US government is moving to restrict Chinese open-weight AI models like DeepSeek and Kimi after repeated distillation warnings. Federal agencies are already cracking down. Whatever you think of the security argument, notice what this actually restricts: the free, downloadable, run-it-yourself tier of frontier AI.

Cancer Institute NSW shared a post on LinkedIn: “At the Institute, our All Staff Meetings bring us together to connect, reflect and learn. In our most recent session, we looked back on the past quarter and explored key topics including psychological safety, time management and AI. We also recognised the following teams and individuals for their outstanding service: Climate Sustainability Award: Internal NetZero Working Group. Empower Them Award: Neil De Leon. Values Champion Award: Angela Cho.

Florian Lordick, Oncologist, Professor of Medicine at University of Leipzig, Head of Medical Oncology, Director of the Comprehensive Cancer Center Central, Germany, shared on LinkedIn: “LUCERNA – moving the field forward for patients with advanced CLDN18.2-positive and PD-L1-positive gastric cancer. Exploring the potential of a biomarker-driven combination strategy to further improve outcomes.

Norman Ng, Director of Patient Advocacy and Public Affairs at Healthcare Thinkers, shared a post on LinkedIn: “Such a meaningful PPIE (Patient and Public Involvement and Engagement) cancer research meeting yesterday! Grateful to Prof Janelle Yorke, Chair Professor of Nursing Head, School of Nursing, Hong Kong Polytechnic University for bringing PPIE to Hong Kong healthcare.

Sara Elena Rebuzzi, Medical Oncologist, MD, PhD at A.O.U. Città della Salute e della Scienza di Torino, shared on LinkedIn: “Great collaboration on the use of Artificial Intelligence for assessing prognostic biomarkers in mRCC patients receiving immunotherapy. This work provides a solid foundation for our upcoming research in the first-line setting.

Juan W. Valle, Chief Medical Officer at Cholangiocarcinoma Foundation, shared on LinkedIn: “Please join us on Sept. 25 for the Chicago Regional Symposium. Keynote speaker Dr. Ethan Ludmir will share important information for patients and caregivers. The agenda is full of expert presentations and opportunities for patients to connect with each other and ask the experts questions directly.

Samantha Mallahan, M.D. Candidate at Loyola University of Chicago Stritch School of Medicine, shared on LinkedIn: “This past week I returned from Kutaisi, Georgia after a 2-week clinical and research site visit to the Krystyna Kiel Oncology Center (KKOC) – an experience I will carry with me for the rest of my career.

Matthew Sikora, Associate Professor at University of Colorado Anschutz Medical Campus, shared on LinkedIn: “They Do exist! Not a bad way to start the week, with a Notice of Award from NCI. Really excited to work with Sean Fanning and Julie Hanson Ostrander to develop ‘purpose-built‘ anti-estrogens tailored to the specific pharmacology of the estrogen receptor in lobular breast cancer.

Michelle Kirschner, Managing Director of the International Cancer Rehabilitation Foundation, Clinical Lead and Medical Advisory Board Chairman at OneVillage, shared on LinkedIn: “Stacy Wentworth, MD Thank you for highlighting this important issue and for referencing my work in your Substack article. I completely agree that meaningful change will require empowering survivors to advocate for their needs during treatment and throughout survivorship.

A routine NFL drug test changed everything for Denver Broncos linebacker Alex Singleton. In early November 2025, mandatory league testing detected elevated levels of human chorionic gonadotropin, commonly known as hCG. The hormone can be used as a tumor marker in some forms of testicular cancer, and the unexpected result prompted Singleton to seek further medical evaluation. An ultrasound subsequently confirmed a testicular tumor.